SPGL008

Phase 2Small molecule

SShenyang Sunshine Pharmaceutical Co., LTD.

SPGL008 is one of 74 small molecule programs targeting Advanced Malignant Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant TumorsRecruiting

EfficacyNot yet recruiting

Advanced Malignant TumorsPhase 1

Recruiting

EfficacyPhase 2

Not yet recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

5 2

Paraplatin

AAvyxa

Phase 3

4 3

Alimta

SShawn Eagle

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 5

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

1 6

Veracept

SSebela Women's Health Inc.

Phase 3

1 7

Levocept

SSebela Women's Health Inc.

Phase 3

1 8

Aralen

Sanofi

Preclinical

2 9

Primaquine

Sanofi

Preclinical

2 10

Proamatine

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Malignant Tumors

NCT07038005

Q4 2029

Phase 2Not yet recruiting

Non-Small Cell Lung Cancer

NCT07874984

Phase 1/2Not yet recruiting

Efficacy

NCT07445308

Clinical

Trials by Indication[1]

Efficacy1 trial

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Not yet recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1/2·NCT07445308·120 enrolled

Advanced Malignant Tumors1 trial

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT07038005·96 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 2 Study of SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer

Not yet recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT07874984·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SPGL008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPGL008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPGL008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

SPGL008

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2029

Trials by Indication[1]

Efficacy1 trial

Advanced Malignant Tumors1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News